Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome

Novartis

Status and phase

Completed

Phase 2

Conditions

Dumping Syndrome

Treatments

Drug: SOM230

Study type

Interventional

Funder types

Industry

Identifiers

NCT01637272

2012-001534-34 (EudraCT Number)

CSOM230X2203

Details and patient eligibility

About

multi-center, phase II study evaluating efficacy, safety and pharmacokinetics of pasireotide in patients with dumping syndrome

Full description

43 adult patients with dumping syndrome received pasireotide s.c. during the dose escalation phase (3 months dose could be increased based on the presence of hypoglycemia during OGTT). After completing Month 3, patients were switched to pasireotide LAR for 3 months (up to Month 6). The core phase of the study was completed at the end of Month 6. Patients were allowed to enter the 6 month extension phase if they experienced benefit with pasireotide LAR treatment.

Enrollment

43 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria:.

Male or female patients ≥ 18 years of age.
Post-gastric or esophageal bypass surgery, matching one of the criteria below:
Bariatric surgery: more than 6 months before signing the informed consent
Esophageal cancer surgery: were disease free at study entry
Gastric cancer surgery: were at stage 0 or I and were disease free at study entry
Patient with a documented diagnosis of Dumping Syndrome defined as having:
History of/or active symptoms associated with dumping syndrome (e.g. post-prandial tachycardia, bloating, diarrhea) and
Documented history of hypoglycemia based on either:
glucose <50 mg/dL or 2.8 mmol/L on a sporadic or scheduled blood analysis -or
glucose value <60 mg/dL or ≤ 3.3 mmol/L at 90, 120, 150 or 180 min during an OGTT
Patients had at least one glucose level <60 mg/dL (or ≤ 3.3 mmol/L) at 90, 120, 150 or 180 min during the 3-hour OGTT at screening.
Patients with esophageal cancer with a negative computed tomography (CT) or Magnetic resonance imaging (MRI) scan (neck, thoracic, and upper abdominal) and albumin

≥ 3.5 g/dl at baseline.
Patients with gastric cancer with a negative CT or MRI scan (total abdomen).
Karnofsky Performance Status ≥ 60 (i.e. required occasional assistance, but was able to care for most of their personal needs)
Patients who received other therapies for dumping syndrome (such as acarbose, gama guar, pectin) must have stopped all treatments and had a wash out period prior to signing the informed consent (i.e. at least 2 weeks between last previous therapy and first dose of study medication in this study).
Patients who had provided signed written informed consent prior to study participation.

Exclusion Criteria:

Bariatric patients who had lap band.
Patients with a current diagnosis of diabetes mellitus.
Patients who had failed treatment with somatostatin analogues for dumping syndrome in the past.
Patients who had been treated with somatostatin analogues in the past, must have had an appropriate interval between the last administration of somatostatin analogues treatment and the study drug as follows
Octreotide sc for ≥ 72 hours
Octreotide LAR for ≥ 56 days (8 weeks)
Lanreotide Autogel for ≥ 98 days (14 weeks)
Lanreotide SR ≥ 28 days (4 weeks)
Patients who were already treated with pasireotide.
Patients who had a known hypersensitivity to somatostatin analogues.
Patients who were receiving anti-cancer therapy (chemotherapy and/or radiotherapy).
Patients who had any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:
Patients with the presence of active or suspected acute or chronic uncontrolled infection or with a history of immunodeficiency, including a positive human immunodeficiency virus (HIV) test result (ELISA and Western blot). An HIV test was not required; however, previous medical history was reviewed.
Non-malignant medical illnesses that were uncontrolled or whose control may have been jeopardized by the treatment with this study treatment.
Life-threatening autoimmune and ischemic disorders.
Patients with the presence of active or suspected acute or chronic uncontrolled infection.

Inadequate end organ function as defined by:

Inadequate bone marrow function:
White blood cells (WBC) <2.5 x 109/L
Absolute neutrophil count <1.5 x 109/L
Platelets <100 x 109/L
Hemoglobin <9 g/dL
International normalized ratio (INR) ≥ 1.3
Serum creatinine >2.0 mg/dL
Alkaline phosphatase (ALP) >2.5 x upper limit of normal (ULN)
Serum total bilirubin >1.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >2 x ULN
History of liver disease, such as cirrhosis or chronic active hepatitis B and C.
Presence of Hepatitis B surface antigen (HbsAg) and/ or presence of Hepatitis C antibody test (anti-Hepatitis C Virus).